We will be contrasting the differences between Edge Therapeutics Inc. (NASDAQ:EDGE) and Celldex Therapeutics Inc. (NASDAQ:CLDX) as far as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edge Therapeutics Inc.	N/A	0.00	N/A	-1.31	0.00
Celldex Therapeutics Inc.	9.54M	6.42	151.18M	-17.46	0.00

Table 1 highlights Edge Therapeutics Inc. and Celldex Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
Edge Therapeutics Inc.	0.00%	-118.1%	-82.7%
Celldex Therapeutics Inc.	-1,584.70%	-93%	-68.2%

Volatility & Risk

Edge Therapeutics Inc. is 267.00% more volatile than S&P 500 due to its 3.67 beta. Celldex Therapeutics Inc.’s 332.00% more volatile than S&P 500 volatility due to the stock’s 4.32 beta.

Liquidity

The Current Ratio and a Quick Ratio of Edge Therapeutics Inc. are 5.6 and 5.6. Competitively, Celldex Therapeutics Inc. has 6.6 and 6.6 for Current and Quick Ratio. Celldex Therapeutics Inc.’s better ability to pay short and long-term obligations than Edge Therapeutics Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Edge Therapeutics Inc. and Celldex Therapeutics Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Edge Therapeutics Inc.	0	0	0	0.00
Celldex Therapeutics Inc.	0	0	1	3.00

Celldex Therapeutics Inc. on the other hand boasts of a $19 average price target and a 286.18% potential upside.

Insider & Institutional Ownership

Institutional investors held 28.2% of Edge Therapeutics Inc. shares and 30.7% of Celldex Therapeutics Inc. shares. Insiders held 11.39% of Edge Therapeutics Inc. shares. Comparatively, insiders own roughly 0.1% of Celldex Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Edge Therapeutics Inc.	14.43%	4.52%	-11.61%	-45.89%	-96.93%	43.27%
Celldex Therapeutics Inc.	-11.7%	-32.65%	16.72%	-31.59%	-84.87%	72.81%

For the past year Edge Therapeutics Inc.’s stock price has smaller growth than Celldex Therapeutics Inc.

Summary

Celldex Therapeutics Inc. beats on 7 of the 10 factors Edge Therapeutics Inc.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.